Drug intelligence / Profile preview

brucine

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Inhalation
01

Overview

**Brucine** is a natural **alkaloid** closely related to strychnine, primarily found in the seeds of *Strychnos nux-vomica* and *Strychnos ignatii*. It is recognized for its **high toxicity**, acting as a poison through paralysis of peripheral nerve endings and inducing convulsions, although it is less potent than strychnine. Brucine has historically been used as a tool in stereospecific syntheses and chiral resolution processes in chemistry because it is a large chiral molecule. In industry, it has served as an alcohol denaturant, reagent for analytical chemistry, and, less commonly today, as a rodenticide. Brucine has limited documented use in medicine due to its toxicity, but it is sometimes mentioned in traditional Chinese medicine and homeopathic preparations, mainly as an anti-inflammatory and analgesic. Its therapeutic window is very narrow, restricting its direct application as a pharmaceutical agent. Brucine is a white, odorless crystalline solid with a very bitter taste and is highly toxic by ingestion and inhalation. Its mechanism of toxicity overlaps with strychnine, exhibiting neurotoxic effects by antagonizing inhibitory neurotransmission, leading to convulsions and central nervous system stimulation[1][3][7][4].

Other names
10,11-dimethoxystrychnine2,3-dimethoxystrychnidin-10-onebrucinumbrucine dihydratebrucine tetrahydrate
02

Targets

Glycine receptor

Beyond the preview

Go deeper on brucine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on brucine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call